Moleculin Biotech (MBRX) Competitors $0.39 0.00 (-0.18%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$0.40 +0.01 (+1.43%) As of 08/29/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX vs. ARTV, RPTX, OVID, MNOV, INMB, ELYM, IMMX, ANL, GNTA, and GANXShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Artiva Biotherapeutics (ARTV), Repare Therapeutics (RPTX), Ovid Therapeutics (OVID), MediciNova (MNOV), INmune Bio (INMB), Eliem Therapeutics (ELYM), Immix Biopharma (IMMX), Adlai Nortye (ANL), Genenta Science (GNTA), and Gain Therapeutics (GANX). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. Its Competitors Artiva Biotherapeutics Repare Therapeutics Ovid Therapeutics MediciNova INmune Bio Eliem Therapeutics Immix Biopharma Adlai Nortye Genenta Science Gain Therapeutics Artiva Biotherapeutics (NASDAQ:ARTV) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation. Do institutionals & insiders have more ownership in ARTV or MBRX? 15.5% of Moleculin Biotech shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by insiders. Comparatively, 2.1% of Moleculin Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, ARTV or MBRX? Moleculin Biotech has lower revenue, but higher earnings than Artiva Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtiva Biotherapeutics$250K307.82-$65.37MN/AN/AMoleculin BiotechN/AN/A-$21.76MN/AN/A Do analysts prefer ARTV or MBRX? Artiva Biotherapeutics presently has a consensus price target of $17.00, indicating a potential upside of 439.68%. Moleculin Biotech has a consensus price target of $4.00, indicating a potential upside of 919.37%. Given Moleculin Biotech's higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Artiva Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ARTV or MBRX more profitable? Artiva Biotherapeutics' return on equity of -42.60% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Artiva BiotherapeuticsN/A -42.60% -37.76% Moleculin Biotech N/A -1,498.41%-114.47% Does the media prefer ARTV or MBRX? In the previous week, Moleculin Biotech had 3 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 7 mentions for Moleculin Biotech and 4 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 1.19 beat Moleculin Biotech's score of 0.31 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moleculin Biotech 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryArtiva Biotherapeutics beats Moleculin Biotech on 6 of the 10 factors compared between the two stocks. Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.90M$3.06B$5.66B$9.84BDividend YieldN/A2.28%3.93%4.04%P/E RatioN/A20.9283.2726.61Price / SalesN/A200.54451.26176.46Price / CashN/A44.0537.7059.65Price / Book-1.648.0710.556.59Net Income-$21.76M-$53.98M$3.27B$266.12M7 Day Performance-30.87%-0.88%0.47%0.17%1 Month Performance-44.81%6.20%5.93%3.03%1 Year Performance-84.61%7.13%48.79%19.98% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech2.9232 of 5 stars$0.39-0.2%$4.00+919.4%-84.6%$11.90MN/A0.0020News CoverageAnalyst ForecastARTVArtiva Biotherapeutics3.0859 of 5 stars$2.76-1.1%$17.00+516.2%-72.1%$66.67M$250K0.0081Positive NewsGap UpRPTXRepare Therapeutics2.7603 of 5 stars$1.55+1.3%$4.50+190.3%-44.5%$66.59M$53.48M-0.60180OVIDOvid Therapeutics4.1434 of 5 stars$0.93-1.1%$3.10+233.3%+6.7%$66.28M$570K-1.7660Positive NewsAnalyst RevisionMNOVMediciNova2.2029 of 5 stars$1.32+1.5%$7.00+430.3%+0.0%$64.25M$1M-5.2810Analyst ForecastGap UpINMBINmune Bio1.9491 of 5 stars$2.37-1.5%$18.40+678.0%-70.4%$62.87M$50K-0.9510ELYMEliem TherapeuticsN/A$2.11+11.1%N/A-68.8%$62.78MN/A-3.989Positive NewsGap UpHigh Trading VolumeIMMXImmix Biopharma3.2768 of 5 stars$2.18-0.7%$7.00+221.8%+4.7%$62.71MN/A-2.829News CoverageAnalyst DowngradeANLAdlai Nortye1.6044 of 5 stars$1.70-0.3%$9.00+431.0%-38.5%$62.55MN/A0.00127Positive NewsGNTAGenenta Science2.3286 of 5 stars$3.39-0.6%$25.00+637.5%-2.8%$62.00MN/A0.007News CoverageGap UpGANXGain Therapeutics2.1167 of 5 stars$1.71+1.2%$7.80+356.1%+86.0%$61.47MN/A-2.7120News CoverageAnalyst Revision Related Companies and Tools Related Companies ARTV Competitors RPTX Competitors OVID Competitors MNOV Competitors INMB Competitors ELYM Competitors IMMX Competitors ANL Competitors GNTA Competitors GANX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBRX) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
